Specific neurotoxicity of chronic use of ecstasy

Toxicol Lett. 2002 Feb 28;127(1-3):285-97. doi: 10.1016/s0378-4274(01)00511-2.

Abstract

The use of the illicit drug ecstasy (mainly containing methylenedioxymethamphetamine, MDMA) is widespread among young people in western Nations. Animal experiments indicate that MDMA is a potent neurotoxin specifically affecting the serotonergic system. A few functional neuroimaging studies revealed central nervous alterations after the repeated use of ecstasy. We examined 94 ecstasy users in comparison to 27 control subjects by means of positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). The FDG uptake rates were globally reduced in ecstasy users, most pronounced in the striatum. The uptake rates tended to be negatively correlated with the cumulative ecstasy doses. The results indicate that younger ecstasy users may be more vulnerable with regard to neurotoxicity.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Female
  • Fluorodeoxyglucose F18 / administration & dosage
  • Fluorodeoxyglucose F18 / pharmacokinetics
  • Glucose / metabolism
  • Hallucinogens / adverse effects*
  • Hallucinogens / pharmacokinetics
  • Humans
  • Linear Models
  • Male
  • N-Methyl-3,4-methylenedioxyamphetamine / adverse effects*
  • N-Methyl-3,4-methylenedioxyamphetamine / pharmacokinetics
  • Nervous System Diseases / chemically induced*
  • Nervous System Diseases / diagnostic imaging
  • Tomography, Emission-Computed

Substances

  • Hallucinogens
  • Fluorodeoxyglucose F18
  • Glucose
  • N-Methyl-3,4-methylenedioxyamphetamine